Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.48
- Piotroski Score 4.00
- Grade Hold
- Symbol (SRDX)
- Company Surmodics, Inc.
- Price $38.40
- Changes Percentage (-0.23%)
- Change -$0.09
- Day Low $38.30
- Day High $38.80
- Year High $42.44
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $39.50
- High Stock Price Target $43.00
- Low Stock Price Target $36.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.96
- Trailing P/E Ratio 43.7
- Forward P/E Ratio 43.7
- P/E Growth 43.7
- Net Income $-11,542,000
Income Statement
Quarterly
Annual
Latest News of SRDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Investors Will Want Surmodics' (NASDAQ:SRDX) Growth In ROCE To Persist
To identify potential multi-bagger stocks, look for growing Return on Capital Employed (ROCE) and expanding capital employed. Surmodics (NASDAQ:SRDX) shows promising trends with an 11% ROCE and increa...
By Yahoo! Finance | 4 months ago
